How Semax Protects the Brain After Stroke: Protein-Level Evidence from a Rat Model | Research

The takeaway

Semax reduced inflammatory and cell-death proteins while activating a recovery protein in rat brains 24 hours after experimentally induced stroke.

4 proteins modulated
Semax downregulated MMP-9, c-Fos, and JNK (inflammation/death) while upregulating CREB (recovery) after stroke

What the researchers found

At 24 hours after transient middle cerebral artery occlusion (tMCAO) in rats, Semax treatment produced measurable changes in four key brain proteins:

- **CREB** (recovery/neuroprotection): Upregulated in subcortical structures, including the ischemic damage focus

- **MMP-9** (inflammation/tissue breakdown): Downregulated in the adjacent frontoparietal cortex

- **c-Fos** (inflammatory signaling): Downregulated in the frontoparietal cortex

- **JNK** (cell death pathway): Downregulated in both subcortical structures and cortex

These protein-level changes are consistent with previous transcriptome data showing Semax suppresses inflammatory gene expression and activates neurotransmitter genes after ischemic injury.

Why it matters

Semax is one of the few peptide drugs actually approved for stroke treatment (in Russia), but the molecular mechanisms behind its protective effects have not been fully understood. This study provides protein-level confirmation that Semax works through a dual mechanism: suppressing inflammation and cell death while activating recovery pathways. Understanding these mechanisms could help optimize Semax dosing and potentially guide the development of similar neuroprotective peptides for broader clinical use.

How the study worked

Researchers used the rat transient middle cerebral artery occlusion (tMCAO) model to simulate ischemic stroke. Semax was administered, and brain tissue was collected at 24 hours post-stroke. Expression profiling of four key proteins — MMP-9, c-Fos, JNK, and CREB — was performed in subcortical structures (including the ischemic core) and the adjacent frontoparietal cortex. Results were integrated with previous genome-wide RNA-Seq data to construct a regulatory network linking transcriptomic and proteomic changes.

What this study cannot tell us

This is a preclinical study in rats, and results may not directly translate to humans. Only four proteins were profiled in detail, representing a small fraction of the molecular changes occurring after stroke. The tMCAO model, while widely used, does not perfectly replicate all aspects of human ischemic stroke. The study examined a single time point (24 hours), so the temporal dynamics of Semax's effects are not captured.

How to read the evidence

This is a preclinical mechanistic study in a rat stroke model. It provides valuable molecular-level insight into Semax's mechanisms but does not directly demonstrate clinical efficacy. The findings are strengthened by consistency with prior transcriptomic data.

When this study was published

Published in 2021, this is a recent study that builds on years of Semax research and uses modern proteomic and transcriptomic approaches.

The bigger picture

Semax belongs to the melanocortin peptide family, which has diverse roles in inflammation, neuroprotection, and neuroplasticity. This study adds to the growing evidence that melanocortin-derived peptides can protect the brain after injury through multiple converging mechanisms. The confirmation of anti-inflammatory and pro-recovery effects at the protein level (not just the gene level) strengthens the case for Semax and may inform development of similar peptides for stroke, traumatic brain injury, and other neurological conditions.

Questions still open

Do these protein-level changes correlate with functional neurological recovery in the rats?
At what time point after stroke is Semax most effective at modulating these protective pathways?
Would similar protein-level neuroprotective effects be seen in human stroke patients receiving Semax?

Common questions

What is Semax and where is it used?

Semax is a synthetic peptide based on a fragment of ACTH (adrenocorticotropic hormone), a natural brain signaling molecule. It was developed in Russia and is approved there for treating ischemic stroke and cognitive disorders. It works by modulating multiple brain pathways involved in inflammation, cell death, and neurological recovery.

How does Semax protect the brain after a stroke?

This study shows Semax works on multiple fronts simultaneously: it reduces proteins that cause inflammation and brain cell death (MMP-9, c-Fos, JNK) while boosting a protein that promotes brain recovery (CREB). This dual action — suppressing damage while activating repair — appears to be the key to its neuroprotective effect.

Read the original research

Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion.

International journal of molecular sciences, 22(12)

View on PubMed ↗Publisher’s paper ↗

Citation

Sudarkina, Olga Yu; Filippenkov, Ivan B; Stavchansky, Vasily V; Denisova, Alina E; Yuzhakov, Vadim V; Sevan'kaeva, Larisa E; Valieva, Liya V; Remizova, Julia A; Dmitrieva, Veronika G; Gubsky, Leonid V; Myasoedov, Nikolai F; Limborska, Svetlana A; Dergunova, Lyudmila V. (2021). Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion.. International journal of molecular sciences, 22(12). https://doi.org/10.3390/ijms22126179